ProCE Banner Activity

On-Demand Webcast: Polycythemia Vera and Myelofibrosis: Expert Perspectives

Multimedia
In this on-demand Webcast of a live symposium in Atlanta, Georgia, expert faculty review optimal care for patients with PV or MF, including differential diagnoses and current and emerging treatment approaches.

Released: January 31, 2018

Expiration: January 30, 2019

No longer available for credit.

Share

Faculty

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

John Mascarenhas

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an educational grant from

Incyte

Learning Objectives

  • Utilize clinical evidence and updated multiparameter criteria to help to distinguish PV and MF from reactive conditions and discriminating among them the Philadelphia chromosome–negative MPNs
  • Discuss the impact of mutational profiling in the management of PV and MF
  • Tailor therapy for patients with high-risk or aggressive PV using evidence-based guidance on best practices, safety considerations, available research data
  • Develop a plan to select second-line therapies for patients with PV who are refractory/relapsed to first-line agents
  • Critically interpret most recent results of clinical trials to optimize treatment/management of MF in the era of JAK inhibition
  • Evaluate the clinical data on promising agents and combination regimens likely to improve outcomes for patients with PV and MF
  • Identify ongoing trials for the treatment of PV to aid referral of patients for study participation

Program Director Disclosure

Program Director

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Blueprint Medicines, Bristol‐Myers Squibb, Celgene, CTI BioPharma, Galena BioPharma, Genentech, Geron, Gilead Sciences, Incyte, Lilly Oncology, NS Pharma, Pfizer, Promedior, Roche, and Seattle Genetics.

Faculty Disclosure

Primary Author

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD, has disclosed that he has received consulting fees from Incyte and Novartis and funds for research support from CTI Biopharma, Incyte, Janssen, Merck, Novartis, Promedior, and Roche.

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Incyte and funds for research support from Constellation.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has disclosed that he has received consulting fees from Incyte.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.